Table 4. Depression scores at baseline (week 0), endpoint (week 10), and score difference (baseline minus endpoint) according to group and investigated single nucleotide polymorphisms (SNPs).
| Placebo | Escitalopram | tDCS | |
|---|---|---|---|
| BDNF | |||
| Met | |||
| Baseline | 21.2 (3.7) | 21.3 (4) | 23 (3.6) |
| Endpoint | 14.8 (6.3) | 9.8 (6.4) | 13.7 (4.9) |
| Difference | 6.3 (6) | 11.5 (7.8) | 9.3 (4.9) |
| Val/Val | |||
| Baseline | 23.3 (4.2) | 22 (3.4) | 20.9 (4.2) |
| Endpoint | 17.5 (9.3) | 10.5 (5.6) | 12.8 (7.2) |
| Difference | 5.9 (8.7) | 11.5 (5.8) | 8.1 (7.6) |
| SLC6A4 | |||
| Short | |||
| Baseline | 22.5 (4.1) | 21.7 (3.9) | 21.7 (4.3) |
| Endpoint | 17.5 (7.6) | 10.7 (6.1) | 12.9 (6.4) |
| Difference | 5 (6.9) | 11 (6.9) | 8.8 (7) |
| Long/Long | |||
| Baseline | 22.6 (4.4) | 21.9 (3.2) | 21.2 (3.6) |
| Endpoint | 14.3 (9.6) | 9.7 (5.5) | 13.6 (7.1) |
| Difference | 8.3 (9.1) | 12.2 (6) | 7.7 (6.7) |
| TPH1 | |||
| T | |||
| Baseline | 22.2 (4) | 21.8 (3.7) | 21.9 (3.9) |
| Endpoint | 16.3 (8.4) | 11.4 (5.9) | 13 (5.7) |
| Difference | 5.9 (7.7) | 10.3 (6.7) | 8.9 (6.1) |
| G/G | |||
| Baseline | 23.2 (4.6) | 21.8 (3.4) | 21.1 (4.6) |
| Endpoint | 16.8 (8.3) | 8.4 (5.4) | 13.2 (7.6) |
| Difference | 6.4 (8) | 13.5 (5.9) | 8 (7.9) |
| COMT | |||
| G | |||
| Baseline | 21.9 (3.3) | 21.6 (3.6) | 21.4 (3.8) |
| Endpoint | 16.4 (7) | 11.4 (4.8) | 12.2 (7) |
| Difference | 5.5 (6) | 10.1 (5.2) | 9.2 (6.6) |
| A/A | |||
| Baseline | 22.8 (4.5) | 21.9 (3.6) | 21.6 (4.2) |
| Endpoint | 16.5 (8.9) | 9.7 (6.3) | 13.4 (6.5) |
| Difference | 6.3 (8.5) | 12.2 (7.1) | 8.3 (7) |
| HTR2A (rs6311) | |||
| T | |||
| Baseline | 23 (4.2) | 21.9 (3.5) | 21.9 (3.3) |
| Endpoint | 17.4 (8.6) | 10.6 (5.7) | 13.4 (5.8) |
| Difference | 5.6 (8.4) | 11.2 (6.6) | 8.6 (6.4) |
| C/C | |||
| Baseline | 21.7 (4) | 21.5 (4.2) | 21 (5.3) |
| Endpoint | 15 (7.9) | 9.2 (6.4) | 12.6 (7.7) |
| Difference | 6.7 (6.7) | 12.3 (6.5) | 8.4 (7.7) |
| HTR2A (rs6313) | |||
| A | |||
| Baseline | 23 (4.2) | 21.8 (3.5) | 22 (3.3) |
| Endpoint | 17.4 (8.6) | 10.5 (5.7) | 13.4 (5.8) |
| Difference | 5.6 (8.4) | 11.2 (6.5) | 8.5 (6.4) |
| G/G | |||
| Baseline | 21.7 (4) | 21.9 (4) | 21 (5.2) |
| Endpoint | 15 (7.9) | 9.5 (6.5) | 12.6 (7.7) |
| Difference | 6.7 (6.7) | 12.4 (6.7) | 8.4 (7.7) |
| HTR2A (rs7997012) | |||
| A | |||
| Baseline | 22.2 (3.9) | 21.9 (3.9) | 21.7 (4.7) |
| Endpoint | 15.8 (8.6) | 9.6 (6.6) | 13.6 (6.8) |
| Difference | 6.4 (8.7) | 12.2 (7.4) | 8 (7.8) |
| G/G | |||
| Baseline | 23 (4.5) | 21.7 (3.4) | 21.5 (3.5) |
| Endpoint | 17.3 (8) | 10.8 (5.2) | 12.5 (6.3) |
| Difference | 5.6 (6.4) | 10.8 (5.7) | 8.9 (6) |
Data presented as mean (standard deviation) scores on the Hamilton Depression Rating Scale, 17-items (HDRS-17).
BDNF = brain-derived neurotrophic factor; COMT = catechol-o-methyltransferase;
SLC6A4 = solute carrier family 6, member 4; tDCS = transcranial direct current stimulation; TPH1 = tryptophan hydroxylase 1.